SK’s Antiepileptic Speeds Japan Entry Via $500m Ono Partnership
Executive Summary
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
You may also be interested in...
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
SK Bio's 2020 Plans Undeterred By Pandemic
The CEO of South Korea's SK Biopharmaceuticals talks about commercialization plans, strategy for epilepsy drug cenobamate and other pipeline assets and planned IPO.
Interview: Arvelle Aims To Be Major Player In CNS
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Need a specific report? 1000+ reports available
Buy Reports